Muro et al. conducted a phase Ib trial (KEYNOTE-012) in 39 patients with PD-L1-positive advanced gastric or GEJ adenocarcinoma to investigate the safety and activity of the anti-PD-1 antibody pembrolizumab [11]. Here, CD274 is linked to gastroesophageal junction adenocarcinoma.